Drugs / Autologous RAK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05738980 | Feb 2023 → Dec 2025 overdue | hepatocellular carcinoma | Beijing Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous RAK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05738980 ↗ |
| Modality | Cell therapy | “Autologous RAK cells were reinfused for treatment” NCT05738980 ↗ |
| Route | Intravenous | “Autologous RAK cells were treated by intravenous reinfusion” NCT05738980 ↗ |